IDT forecasts first positive EBITDA as FY27 revenue reaches $20 million
IDT Australia expects FY27 revenue of $19 million to $20 million and EBITDA of $1 million to $1.5 million, marking a projected swing from a $0.92 million FY26 loss. The forecast rests on larger customer contracts, a five-year radiopharmaceutical deal and roughly $7 million of manufacturing upgrades.
- FY27 revenue guidance of $19 million to $20 million, up 13% to 19%
- EBITDA forecast of $1 million to $1.5 million after a $0.92 million FY26 loss
- Larger contracts and a strategic reset underpin the projected earnings improvement
- Approximately $7 million being invested in sterile and oral dose manufacturing
- Three-year ambition to reach $50 million in annual revenue
Add us as a preferred source on Google
FY27 Guidance Points to Positive EBITDA
IDT Australia Limited (ASX:IDT) is forecasting its first positive EBITDA in the figures disclosed for FY27, with earnings expected to reach $1 million to $1.5 million after a FY26 loss of $0.92 million. Revenue from its three operating verticals is forecast at $19 million to $20 million, representing growth of 13% to 19% on FY26 actual revenue of $16.8 million.
The improvement is expected to come from key client contracts scheduled to commence in the second half of FY27, alongside the effects of a strategic reset launched early in FY26. That timing matters: the forecast is not evenly supported across the year, and delivery will depend partly on when customer programmes begin.
Strategic Reset Shifts IDT Towards Larger Contracts
IDT says it is trying to reduce the revenue lumpiness common in contract development and manufacturing by building a deeper backlog across its three business verticals. The stated aim is to improve project visibility, reduce dependence on individual contracts and make better use of manufacturing capacity when customer programmes are delayed.
The company is also prioritising larger, better-resourced pharmaceutical and biotechnology customers, while retaining emerging biotech as an important segment. Several higher-value contracts are already contributing to the FY27 outlook. The shift builds on the $7.3 million capability program, which earlier coverage identified as an investment in sterile and solid oral manufacturing.
Sterile Manufacturing Investment Supports Growth Target
IDT is targeting $50 million of annual revenue within three years, supported by expansion into new markets, a growing opportunity pipeline and deeper relationships with key clients. Its approximately $7 million upgrade programme is focused on advanced sterile and oral dose manufacturing, capabilities the company says will improve its ability to compete for larger contracts.
The investment has already helped IDT secure a further five-year contract with an existing radiopharmaceutical customer, according to the announcement. The same global pharmaceutical customer has also expressed interest in developing its relationship with IDT beyond research and development work. Separately, the company says its relationship with Sanofi is deepening; Sanofi was previously reported as having named IDT a preferred Sanofi vendor.
Contract Timing Remains the Key Test
The guidance is materially stronger than FY26 actual performance, but it remains a forecast rather than delivered earnings. The announcement gives no contract values, margin guidance, cash flow forecast or funding detail for the upgrade programme. It also acknowledges that customer timing is a source of volatility in the CDMO model.
That leaves execution as the central question for FY27: whether the committed contracts start as planned, whether the upgraded facilities are utilised at a higher level and whether new work can turn a more promising pipeline into repeatable revenue. The next evidence will come from contract commencement and operating performance in the second half of the financial year.
Bottom Line?
The forecast marks a sharp earnings reset, but IDT still needs timely contract starts and higher facility utilisation to convert capacity investment into recurring cash-generating growth.
Questions in the middle?
- Will the key contracts scheduled for the second half of FY27 commence on time and at the scale assumed in guidance?
- How quickly can the sterile and oral dose upgrades translate into higher utilisation and margins?
- Can IDT build enough recurring work to progress from $20 million of forecast revenue towards its $50 million target without renewing the industry’s revenue lumpiness?
Sources
1-
FY27 Earnings Guidance & Operating Update (opens in a new tab)Official market announcement. Idt Australia Limited · 18 Nov 2026 · idtaus.com.au